Evaluation for the Effectiveness and Safety of Cryo-ablation in the Treatment of Early Invasive Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

186 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-01

Study Completion Date

2025-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recently, researchers in America reported a clinical research (Alliance Z1072) which proved that cryo-ablation could be considered as a non-surgical treatment of early-stage breast cancer. The long term effectiveness and safety of cryo-ablation in early invasive breast cancer is still unknown. Therefore, this prospective study are designed to evaluate the effectiveness and safety of cryo-ablation in early invasive breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

NCT00723294

Breast Cancer

UNKNOWN PHASE2

FreezIng bReaST Cancer in Brazil: a Before-after Study

NCT05398497

Breast Cancer Breast Neoplasms

UNKNOWN NA

Comparison of Microwave Ablation With Cryoablation for Breast Tumor

NCT03286413

Breast Tumor Microwave Ablation Cryoablation

UNKNOWN NA

A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients

NCT07238894

Ablation Breast Cancer

RECRUITING NA

Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients

NCT04320979

Breast Cancer

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cryo-ablation group

In the first stage, for patients who meet the criteria, cryo-ablation will be conducted for the lump of invasive breast cancer, and traditional surgery will be conducted within 32days after cryo-surgery. In the second stage, for patients who meet the criteria, cryo-ablation will be conducted, and 5-year effectiveness and safety will be evaluated subsequently.

Group Type EXPERIMENTAL

cryo-ablation

Intervention Type DEVICE

Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cryo-ablation

Under the guide of ultrasound, cryo-ablation for the lump of early invasive breast cancer will be conducted.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

stage 1:

1. female
2. ≥18 years old
3. invasive ductal carcinoma proved by core needle biopsy. Other type of breast cancer should be well considered and decided by investigators. Pathological report should be complete (with the result of ER, PR , HER2, KI67 etc., and FISH report of ERBB2 gene if necessary).
4. lump can be detected by ultrasound.
5. image results (including ultrasound, mammography and MR image) prove the lump is single-center, the maximum diameter of the lump \<2cm.
6. with enough breast tissue, and enough space from lump to skin.
7. patients is not pregnant and has no plan for pregnancy in 2 years.
8. ECOG level: 0-2
9. serum creatinine≤1.1 mg/dl
11. patients are accessible for the follow up and mentally healthy.

stage 2:

1. female
2. ≥18 years old
3. invasive ductal carcinoma proved by core needle biopsy. Other type of breast cancer should be well considered and decided by investigators. Pathological report should be complete (with the result of ER, PR , HER2, KI67 etc., and FISH report of ERBB2 gene if necessary).
4. lump can be detected by ultrasound.
5. image results (including ultrasound, mammography and MR image) prove the lump is single-center, the maximum diameter of the lump \<1.5cm.
6. with enough breast tissue, and enough space from lump to skin.
7. clinically N0 before cryo-ablation.
8. patients is not pregnant and has no plan for pregnancy in 2 years.
9. ECOG level: 0-2
10. serum creatinine≤1.1 mg/dl
12. patients are accessible for the follow up and mentally healthy.

Exclusion Criteria

stage 1:

1. \< 18 years old
2. male
3. the same side breast of the lump have been treated by surgery or other physical treatment within 3months.
4. benign tumor or tumor in situ or tumor in situ with micro-invasion proved by core needle biopsy. Pathological report is not complete (with the result of ER, PR , HER2, KI67 etc., and FISH report of ERBB2 gene if necessary).
5. image results (including ultrasound, mammography and MR image) prove the lump is multi-center, the maximum diameter of the lump ≥2cm.
6. image results (including ultrasound, mammography) prove calcium region ≥ 5mm
7. lump can not be clearly detected by ultrasound. For example, the boundary of tumor is not clear, or the maximum diameter detected by MRI is more than 1.5 times larger than the maximum diameter detected by ultrasound.
8. before the endpoint, patients is treated by other local treatment.
9. ECOG Level \>2
10. serum creatinine\>1.1 mg/dl
11. patients are not accessible for the follow up and mentally unhealthy.
12. patients are pregnant or lactating, or have plan for pregnancy in 2 years.
13. other situations which make patients not suitable for the trail or cryo-ablation.

stage 2:

1. \< 18 years old
2. male
3. the same side breast of the lump have been treated by surgery or other physical treatment within 3months.
4. benign tumor or tumor in situ or tumor in situ with micro-invasion proved by core needle biopsy. Pathological report is not complete (with the result of ER, PR , HER2, KI67 etc., and FISH report of ERBB2 gene if necessary).
5. absolute contraindication for breast conserving surgery.
6. image results (including ultrasound, mammography and MR image) prove the lump is multi-center, the maximum diameter of the lump ≥1.5cm.
7. image results (including ultrasound, mammography) prove calcium region ≥ 5mm
8. lump can not be clearly detected by ultrasound. For example, the boundary of tumor is not clear, or the maximum diameter detected by MRI is more than 1.5 times larger than the maximum diameter detected by ultrasound.
9. NOT clinically N0 before cryo-ablation.
10. patients are treated after neoadjuvant chemotherapy or neoadjuvant endocrine therapy.
11. patients with advanced breast cancer or other type of cancers.
12. with BRCA1/2 mutation
13. before the endpoint, patients is treated by other local treatment.
14. ECOG Level \>2
15. serum creatinine\>1.1 mg/dl
16. can not finish the radiotherapy afterwards or with contraindication of radiotherapy
17. patients are not accessible for the follow up and mentally unhealthy.
18. patients are pregnant or lactating, or have plan for pregnancy in 2 years.
19. other situations which make patients not suitable for the trail or cryo-ablation.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No